Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal

Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal

Source: 
Fierce Biotech
snippet: 

Merck KGaA’s new R&D strategy is continuing to run apace, with the company ramping up efforts to more swiftly sign onto and offload assets that have commercial potential.